[Liprimar in prevention of coronary complications in patients following reconstructive vascular surgery].
The article is dedicated to analyzing the outcomes of an open prospective study of efficacy of Liprimai administered in the postoperative period. The study comprised a total of 30 patients presenting with atherosclerotic lesions of the arteries of the carotid bed and aorto-femoral segment, who were subjected to reconstructive vascular operations. The aim of the present study was to look into a possibility of preventing cardiac complications in patients after endured reconstructive vascular surgery. Liprimar was administered at a daily dose of 10 mg seven days prior to the operation, and for eight days thereafter.
Department of Vascular Surgery, A. V. Vishnevsky Institute of Surgery, Russian Academy of Medical Sciences, Moscow, Russia.
A V
AV
Pokrovskiĭ
A E
AE
Zotikov
A A
AA
Shubin
G A
GA
Perisaev
M V
MV
Il'ina
L O
LO
Ivanov
D S
DS
Suntsov
S A
SA
Il'in
D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002340:Carotid Artery Diseases / Q000401:mortality / Q000601:surgery*; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007925:Leriche Syndrome / Q000401:mortality / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011183:Postoperative Complications / Q000517:prevention & control*; D011300:Preoperative Care; D011446:Prospective Studies; D012720:Severity of Illness Index; D014656:Vascular Surgical Procedures / Q000379:methods*
D000924:Anticholesteremic Agents; D002784:Cholesterol